Cefmetazole
A cephamycin-type beta-lactam antibiotic with activity against anaerobic bacteria in addition to gram-positive and gram-negative aerobic organisms. It is used primarily for intra-abdominal, pelvic, and skin infections requiring anaerobic coverage. It also contains the N-methylthiotetrazole group and should be used cautiously with alcohol.
Peso Molecular
471,5000 g/mol
LogP
-0,60
TPSA
239,00 Ų
Regra dos 5 de Lipinski
Aprovado
Mecanismo de Ação
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell …
Estrutura 2D
Cite this structure
Embed this structure
SMILES
CO[C@@]1(NC(=O)CSCC#N)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CS[C@@H]21
InChI
InChI=1S/C15H17N7O5S3/c1-21-14(18-19-20-21)30-6-8-5-29-13-15(27-2,17-9(23)7-28-4-3-16)12(26)22(13)10(8)11(24)25/h13H,4-7H2,1-2H3,(H,17,23)(H,24,25)/t13-,15+/m1/s1
Molecular Formula
C15H17N7O5S3
HBD / HBA
2 / 12
Ligações Rotacionáveis
9
Átomos Pesados
30
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
A cephamycin-type beta-lactam antibiotic with activity against anaerobic bacteria in addition to gram-positive and gram-negative aerobic organisms. It is used primarily for intra-abdominal, pelvic, and skin infections requiring anaerobic coverage. It also contains the N-methylthiotetrazole group and should be used cautiously with alcohol.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.
Yes, Cefmetazole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201195. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 42008. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cefmetazole"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cefmetazole/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cefmetazole/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cefmetazole/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cefmetazole"></drugfyi-drug>